Michael Barbella, Managing Editor01.11.23
Elucid Inc. has added Michael D. Lesh, M.D., FACC, to its Board of Directors.
“We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech executive, and technological innovator. His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” CEO Blake Richards said.
Lesh is currently CEO and founder of Syntegra, a company focused on privacy-preserved synthetic data that bridges the gap between an organization’s data privacy and data science needs. He is also executive chairman at Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. Lesh is a professor of Medicine and former chief of Cardiac Electrophysiology at University of California, San Francisco (UCSF).
Lesh has a background in biomedical engineering and computer science from MIT. He underwent medical training at UCSF and the University of Pennsylvania. He has written more than 200 scientific papers, book chapers, and books, and is an inventor on more than 250 patents.
“I am honored to bring my experience as a cardiologist and inventor entrepreneur to the Elucid board during this time of rapid growth for Elucid and the cardiac imaging field,” Lesh said. “The Elucid technology is poised to become the standard of care for non-invasive diagnosis of cardiovascular disease, and I look forward to working with the company to make this a reality.”
Elucid is a Boston-based company that has developed a non-invasive image analysis software designed to understand the biology of cardiovascular disease. Elucid’s patented PlaqueIQ technology is the only U.S. Food and Drug Administration-cleared and CE-marked analysis software that objectively quantifies plaque morphology validated against tens of thousands of tissue samples and, with an investigational tool, derives FFRCT from these plaque measurements. Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. The Elucid Plaque Analysis software is available for commercial use in the United States, Europe, and South Korea.
“We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech executive, and technological innovator. His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” CEO Blake Richards said.
Lesh is currently CEO and founder of Syntegra, a company focused on privacy-preserved synthetic data that bridges the gap between an organization’s data privacy and data science needs. He is also executive chairman at Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. Lesh is a professor of Medicine and former chief of Cardiac Electrophysiology at University of California, San Francisco (UCSF).
Lesh has a background in biomedical engineering and computer science from MIT. He underwent medical training at UCSF and the University of Pennsylvania. He has written more than 200 scientific papers, book chapers, and books, and is an inventor on more than 250 patents.
“I am honored to bring my experience as a cardiologist and inventor entrepreneur to the Elucid board during this time of rapid growth for Elucid and the cardiac imaging field,” Lesh said. “The Elucid technology is poised to become the standard of care for non-invasive diagnosis of cardiovascular disease, and I look forward to working with the company to make this a reality.”
Elucid is a Boston-based company that has developed a non-invasive image analysis software designed to understand the biology of cardiovascular disease. Elucid’s patented PlaqueIQ technology is the only U.S. Food and Drug Administration-cleared and CE-marked analysis software that objectively quantifies plaque morphology validated against tens of thousands of tissue samples and, with an investigational tool, derives FFRCT from these plaque measurements. Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. The Elucid Plaque Analysis software is available for commercial use in the United States, Europe, and South Korea.
